Anthony J Grady1, Jane S Hankins2, Brent Haberman3, Robert Schoumacher3, Rose Mary Stocks4. 1. Department of Otolaryngology, Head and Neck Surgery, University of Tennessee Health Science Center, 910 Madison Avenue, Suite 420, Memphis, TN, 38163, USA. agrady2@uthsc.edu. 2. Department of Hematology, St. Jude Children's Research Hospital, 262 Danny Thomas place, Memphis, TN, 38105, USA. 3. Department of Pediatric Pulmonology, University of Tennessee Health Science Center, 50 N. Dunlap, 534R W Patient Tower, LBCMC, Memphis, TN, 38103, USA. 4. Department of Otolaryngology, Head and Neck Surgery, University of Tennessee Health Science Center, 910 Madison Avenue, Suite 420, Memphis, TN, 38163, USA.
Abstract
BACKGROUND: While hydroxyurea is the mainstay of treatment for many of the comorbidities associated with sickle cell disease, its effect on obstructive sleep apnea has not been fully investigated. The purpose of this project is to help characterize the effects of hydroxyurea on obstructive sleep apnea in children with sickle cell disease and determine its therapeutic role in the condition. METHODS: Chart review was conducted on two pediatric patients with sickle cell disease who experienced resolution of obstructive sleep apnea following hydroxyurea administration. RESULTS: After undergoing approximately 11 months of hydroxyurea therapy, sleep apnea symptoms improved and obstructive sleep apnea resolution was confirmed by repeat polysomnography in both cases. This resolution was largely secondary to a reduction in the obstructive component of the apnea hypopnea index, highlighting a previously unreported association. CONCLUSIONS: As adenotonsillectomy is associated with significant risks in patients with sickle cell disease, it appears reasonable to consider a period of observation for improvement of obstructive sleep apnea following hydroxyurea administration rather than directly proceeding with surgery.
BACKGROUND: While hydroxyurea is the mainstay of treatment for many of the comorbidities associated with sickle cell disease, its effect on obstructive sleep apnea has not been fully investigated. The purpose of this project is to help characterize the effects of hydroxyurea on obstructive sleep apnea in children with sickle cell disease and determine its therapeutic role in the condition. METHODS: Chart review was conducted on two pediatric patients with sickle cell disease who experienced resolution of obstructive sleep apnea following hydroxyurea administration. RESULTS: After undergoing approximately 11 months of hydroxyurea therapy, sleep apnea symptoms improved and obstructive sleep apnea resolution was confirmed by repeat polysomnography in both cases. This resolution was largely secondary to a reduction in the obstructive component of the apnea hypopnea index, highlighting a previously unreported association. CONCLUSIONS: As adenotonsillectomy is associated with significant risks in patients with sickle cell disease, it appears reasonable to consider a period of observation for improvement of obstructive sleep apnea following hydroxyurea administration rather than directly proceeding with surgery.
Authors: Carol L Rosen; Michael R Debaun; Robert C Strunk; Susan Redline; Sinziana Seicean; Daniel I Craven; Johanna C D Gavlak; Olu Wilkey; Baba Inusa; Irene Roberts; R Lucas Goodpaster; Beth Malow; Mark Rodeghier; Fenella J Kirkham Journal: Pediatrics Date: 2014-07-14 Impact factor: 7.124
Authors: Ronald D Chervin; Susan S Ellenberg; Xiaoling Hou; Carole L Marcus; Susan L Garetz; Eliot S Katz; Elise K Hodges; Ron B Mitchell; Dwight T Jones; Raanan Arens; Raouf Amin; Susan Redline; Carol L Rosen Journal: Chest Date: 2015-11 Impact factor: 9.410
Authors: Jane S Hankins; Russell E Ware; Zora R Rogers; Lynn W Wynn; Peter A Lane; J Paul Scott; Winfred C Wang Journal: Blood Date: 2005-10-01 Impact factor: 22.113
Authors: Christopher D Reiter; Xunde Wang; Jose E Tanus-Santos; Neil Hogg; Richard O Cannon; Alan N Schechter; Mark T Gladwin Journal: Nat Med Date: 2002-11-11 Impact factor: 53.440
Authors: A Ferster; C Vermylen; G Cornu; M Buyse; F Corazza; C Devalck; P Fondu; M Toppet; E Sariban Journal: Blood Date: 1996-09-15 Impact factor: 22.113
Authors: Carole L Marcus; Reneé H Moore; Carol L Rosen; Bruno Giordani; Susan L Garetz; H Gerry Taylor; Ron B Mitchell; Raouf Amin; Eliot S Katz; Raanan Arens; Shalini Paruthi; Hiren Muzumdar; David Gozal; Nina Hattiangadi Thomas; Janice Ware; Dean Beebe; Karen Snyder; Lisa Elden; Robert C Sprecher; Paul Willging; Dwight Jones; John P Bent; Timothy Hoban; Ronald D Chervin; Susan S Ellenberg; Susan Redline Journal: N Engl J Med Date: 2013-05-21 Impact factor: 91.245
Authors: A Parker Ruhl; S Christy Sadreameli; Julian L Allen; Debra P Bennett; Andrew D Campbell; Thomas D Coates; Dapa A Diallo; Joshua J Field; Elizabeth K Fiorino; Mark T Gladwin; Jeffrey A Glassberg; Victor R Gordeuk; Leroy M Graham; Anne Greenough; Jo Howard; Gregory J Kato; Jennifer Knight-Madden; Benjamin T Kopp; Anastassios C Koumbourlis; Sophie M Lanzkron; Robert I Liem; Roberto F Machado; Alem Mehari; Claudia R Morris; Folasade O Ogunlesi; Carol L Rosen; Kim Smith-Whitley; Danna Tauber; Nancy Terry; Swee Lay Thein; Elliott Vichinsky; Nargues A Weir; Robyn T Cohen; Elizabeth S Klings Journal: Ann Am Thorac Soc Date: 2019-09
Authors: Don Hayes; Kevin C Wilson; Katelyn Krivchenia; Stephen M M Hawkins; Ian M Balfour-Lynn; David Gozal; Howard B Panitch; Mark L Splaingard; Lawrence M Rhein; Geoffrey Kurland; Steven H Abman; Timothy M Hoffman; Christopher L Carroll; Mary E Cataletto; Dmitry Tumin; Eyal Oren; Richard J Martin; Joyce Baker; Gregory R Porta; Deborah Kaley; Ann Gettys; Robin R Deterding Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 21.405